KdT Ventures Partners, Mack Healy & Rima Chakrabarti take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This episode, Amylyx Pharmaceuticals, a neuro biotech founded in a dorm room by two scrappy Brown undergrads. We discuss:

• the mechanism of action of Amylyx’s lead disease-modifying asset, and competitive positioning relative to other treatments for neurodegeneration such as aducanumab 

• Amylyx’s capital efficiency, and reaching PhII trials without a single institutional investor

• Amylyx’s unique engagement of ALS patients from the earliest days of the company, helping ensure a strong commercial launch of their ALS therapy

• and more

For updates from KdT, please subscribe to our Substack.